Recent News

• 08.03.2026 - CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
• 08.03.2026 - CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
• 05.28.2026 - CRISPR Therapeutics to Participate in Upcoming Investor Conferences
• 05.06.2026 - CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
• 05.04.2026 - CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
• 04.07.2026 - CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
• 03.11.2026 - CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
• 03.10.2026 - CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
• 02.12.2026 - CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• 01.12.2026 - CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Recent Filings

• 08.03.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.03.2026 - 8-K Current report
• 08.03.2026 - EX-99.1 EX-99.1
• 07.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2026 - 4 Statement of changes in beneficial ownership of securities